We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generics Group Cries Foul Over Biosimilar Exclusivity Provision in USMCA Trade Deal
Generics Group Cries Foul Over Biosimilar Exclusivity Provision in USMCA Trade Deal
A provision in the proposed U.S.-Mexico-Canada Agreement that would give branded biologics makers a decade of exclusivity goes against the White House’s stated priority of improving access to biosimilars, according to the Association for Accessible Medicines (AAM).